Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Clinical trial NCT02031419 · TERMINATED

Trial details

NCT number: NCT02031419
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse

Start date: 2013-12-18
Primary completion: 2023-12-12
Enrollment: 174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.